Business Daily Media

Men's Weekly

.

U.S. FDA Approves Eisai's Dayvigo (Lemborexant) for Treatment of Insomnia in Adult Patients

  • Written by ACN Newswire - Press Releases

image

TOKYO, Dec 23, 2019 - (JCN Newswire) - Eisai Co., Ltd. today announced that the U.S. Food and Drug Administration (FDA) approved the new drug application for its in-house discovered and developed orexin receptor antagonist DAYVIGOTM (lemborexant). DAYVIGO was approved for the treatment of insomnia characterized by difficulties with sleep onset

Read more //?#

Payroll Under Pressure: Why Mid-Sized SMEs Struggle to Keep Pay Accurate

A year after wage theft reforms came into effect, Australian businesses have increased their focus on payroll compliance, but confidence in pay accu...

Refunds to Revenue: AI and loyalty perks help retailers in post-holiday hangover

Australian retailers are turning to artificial intelligence to simplify and automate returns and exchanges, while strengthening loyalty programs a...

Stop reading from the script: Why authenticity is the customer success secret weapon

I’ve been in customer service for years now. As my team has grown, the number one piece of advice I give is to be your...

From Check-in to Touchdown: How AI and smarter systems are transforming the travel industry

Richard Valente, VP of Customer Experience Strategy at TP in Australia, explores how IT-BPM outsourcing is revolutionising the travel sector throu...

Online Christmas shoppers fund climate and biodiversity projects via HealthPost's Click Sphere for Good initiative

Online shoppers with HealthPost’s Flora & Fauna have made 11,000 contributions towards climate and biodiversity projects when ordering parcel ...

US landmark settlement protects SMEs, highlighting flaws in the RBA's proposed blanket card surcharging ban for Australia

Aussie SMEs warn RBA not to ignore global trends, with the current sledgehammer approach threatening business viability and increasing inflation ...